Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages ar
- Posted on July 27, 2026
- By Business News Today
- 0 Views
- 1 min read
In brief
Generating AI summary…
Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages ar
Dr Lal Path Labs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomura, Nuvama and JM Financial raised target prices, citing robust growth outlook, network expansion and improving margins, with continued momentum expected from diagnostics demand and strategic investments.
